Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,203.20
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.82
(
-0.38%
)
Bitcoin
78,197.86
(
-0.10%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 245576

Thursday, 05/04/2023 6:04:28 PM

Thursday, May 04, 2023 6:04:28 PM

Post# of 257441
APLS’ Syfovre has_impressive_first_month—contrary to my skepticism about the drug’s efficacy:

https://www.globenewswire.com/news-release/2023/05/04/2662038/0/en/Apellis-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results.html

APLS sold $18.4M of Syfovre during March (the commercial launch was 3/1/23). Some of this may be a stocking bolus by medical practices.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today